

Minireview Article

A review on Anthracycline induced cardiotoxicity- A mechanistic approach

ABSTRACT

Doxorubicin has become one of the most effective chemotherapeutic agents, but its use was complicated by the development of heart failure. Proposed mechanisms for its antitumor effects included intercalation into DNA that caused the prevention of micro molecule synthesis, reactive oxygen species (ROS) generation, DNA binding and cross-linkage, and DNA damage by topoisomerase 2b (TOP2b) suppression and induction of apoptosis. Several drugs such as ACE inhibitors or the angiotensin receptor blockers (ARB), beta-blockers and the CHF therapy are used for the treatment processes. The present brief review of the literature, focuses on literature based on the mechanism of anthracycline-induced cardiotoxicity.

Keywords: Cytotoxicity, cardiotoxicity, anthracycline, doxorubicin, daunorubicin

1. INTRODUCTION

Anthracyclines (doxorubicin, daunorubicin, epirubicin, aclarubicin, mitoxantrone and idarubicin) are tremendously important in the treatment of lymphomas, breast cancer, leukemia, and soft tissue sarcomas [1]. They were derived as fermentation products of *Streptococcus verticillus* and exert their anticancer activity by their capability to cause DNA fragmentation [2]. The dose dependant cardiac toxicity induced by anthracyclines restricted their effectiveness as an anticancer agent. Anthracycline administration is associated with dose-related cardiomyocyte injury and death leading to LV dysfunction and heart failure. Table 1 represents the several types of cancer associated to anthracycline chemotherapy. The risk factors for cardiac toxicity induced by anthracycline are cumulative dose, age, radiation therapy, concomitant chemotherapy etc.

Although doxorubicin has become one of the most effective chemotherapeutic agents, but its use was complicated by the development of heart failure [3,4]. In a retrospective analysis of over 4000 patients receiving doxorubicin performed by Von Hoff and colleagues [4], 2.2% of the patients developed clinical signs and symptoms of congestive heart failure.

The present review of the literature, focuses on mechanism of anthracycline-induced cardiotoxicity. A comprehensive literature review has been conducted. A bibliographic search was performed in the sciencedirect, Medline, PubMed, Scopus and Web of Science databases. Databases were searched thoroughly using the key words such as cardiotoxicity, Anthracyclines, risk factors, prevention and treatment, combined with cardiotoxicity, breast cancer, cardiomyopathy or heart failure.

Table 1: Various types of cancer responsive to anthracycline chemotherapy

Carcinoma	Lymphoma	Leukaemia	Sarcoma
Breast [5], small cell lung [6] bladder [7], oesophagus [8,9], stomach [9], liver [10] and thyroid [11]	Hodgkin's disease [12] Non-Hodgkin's Lymphoma [13] Cutaneous T-cell Lymphoma [14]	Acute Lymphoblastic [15] Acute Myeloblastic [16]	Osteogenic bone [17] Soft tissue Ewing [18]

1.1 Mechanism of Cytotoxicity

A major part of the anticancer effect of doxorubicin might be due to irreversible damage of tumour cell DNA. Proposed mechanisms for its antitumor effects included intercalation into DNA that caused prevention of micro molecule synthesis, reactive oxygen species (ROS) generation, DNA binding and cross-linkage and DNA damage by topoisomerase 2b (TOP2b) suppression and induction of apoptosis [19-21]. TOP2b was recently identified as doxorubicin-induced cardiotoxicity mediator in a

rat model [22]. TOP2b unwinds DNA strands during replication, transcription or recombination and is present in all quiescent cells, including cardiomyocytes [23,24]. Doxorubicin has been known as a TOP2b poison that prevented DNA synthesis by intercalation into DNA strands. TOP2b changes DNA topology, which leads to transient breakage of double-strand DNA and DNA supercoil dysregulation that can result in cardiomyocyte death [25].

1.2 Mechanisms of Cardiotoxicity

Chemotherapeutic cardiac toxicity can be categorized as either type I (early onset) or type II (late onset) [26,27] based on the effect of the agent on cardiomyocytes [28,29]. Type I cardiotoxicity is produced by cardiomyocyte death, either through apoptosis or necrosis, and as a result is irreversible usually caused by anthracyclines and chemotherapeutics. Type II cardiotoxicity is reversible caused by cardiomyocyte dysfunction rather than cell death [30]. Understanding the etiology of anthracycline cardiac toxicity has allowed the development of preventive strategies to combat the development of permanent cardiac damage.

The precise mechanism of anthracycline-induced cardiac toxicity remains unclear. The most commonly accepted hypothesis was that anthracyclines interfered with redox cycling, resulting in DNA damage due to reactive oxygen species (ROS) production [31]. More recently, topoisomerase 2 has been suggested to be the main mediator of cardiotoxicity [32,33].

1.3 Cardiotoxicity through Reactive Oxygen Species


The molecular base of drug cardiac toxicity is the production of ROS in heart cell mitochondria. The quinone moieties of anthracyclines are subject to univalent reduction to a semiquinone radical by a several cellular oxido-reductases. In myocardial cells, this is mostly achieved through an enzymatic pathway containing NADH dehydrogenase (complex I) of the mitochondrial electron transport chain [34]. The semiquinone auto-oxidises to produce the parent anthracycline and a superoxide anion in presence of molecular oxygen. [35]. The non-enzymatic pathway permits a self-perpetuating redox cycle to be established, leads to the accumulation of superoxide anions. ROS levels may also be increased by free cellular iron and potentiating ferrous-ferric cycling of molecular iron [36]. The doxorubicin-iron complexes form toxic radical and reactive nitrogen species leads to increased nitrosative stress and mitochondrial dysfunction [37].

1.4 Cardiotoxicity through Topoisomerase 2 β

The topological changes during DNA replication, transcription, recombination and chromatin remodelling regulated by DNA topoisomerases (Top) induce temporary single or double-stranded breaks [38]. Top2 is expressed as isoenzymes Top2 α and Top2 β in humans [39]. Among both the isoenzyme, Top2 α is the most predominant and is greatly expressed in proliferating non-malignant and malignant cells. It is crucial for chromosomal segregation and its expression fluctuates through the cell cycle, peaking during G2/M phases [40]. On the contrary, Top2 β is more abundant in quiescent cells, for example adult mammalian cardiomyocytes, and its expression rests constant during the cell cycle.

Doxorubicin exerts its anticancer activity by intercalating DNA. Topoisomerase 2 and DNA bind with doxorubicin forming a Top2-doxorubicin-DNA ternary complex, which leads to double-stranded DNA breaks. When bound to Top2 α , the ternary complex arrests the cell cycle in G1/G2; inhibits DNA replication and induces apoptosis [41] as proposed in proliferating malignant cells. Conversely, when bound to Top2 β , peroxisome proliferator-activated receptor (PPAR) which controls oxidative metabolism gets suppressed and results in mitochondrial dysfunction [42]. In adult mammalian cardiomyocytes, this leads to an activation of altered P53 tumour suppressor pathway, impaired calcium handling, β -adrenergic signalling, mitochondrial dysfunction and increased apoptosis. Doxorubicin cannot bind directly to DNA without Top2 β [41]. Animal studies with Top2 β knockout mice have demonstrated that the absence of Top2 β protects against doxorubicin-induced cardiac toxicity [43,44] partially because of reduced mitochondrial dysfunction [44].

ANTICANCER MECHANISM



CARDIOTOXICITY MECHANISM




Fig. 1. Anticancer and cardiotoxicity mechanism of Anthracycline

1.5 Treatment of anthracycline cardiotoxicity

Several drugs such as ACE inhibitors or the angiotensin receptor blockers (ARB), beta-blockers and the CHF therapy are used for the treatment processes. The use of these agents can help to stabilize the LV systolic functioning [45]. Only nebivolol or carvedilol beta-blockers can be used but any ACE inhibitor or ARB can be used for anthracycline cardiovascular toxicity. Experts of the domain opine that an early diagnosis can always lead to better treatment. Such treatment often involves a high expenditure [46]. Relentless LVEF monitoring which is noninvasive in nature can be a better cost-effective method through which CHF can be prevented [47]. Dexrazoxane is an iron chelator, which reduces Cardiotoxicity of anthracyclines. However, adverse effects including myelotoxicity and concerns about leukemia have limited its use in clinical practice. This is approved for use only in patients receiving >300 mg/m² of doxorubicin [48].

2. Conclusion

Anthracyclines are one of the most important drugs in the treatment of breast cancer. Therefore, while using these drugs, the risk factors associated with cardiotoxicity should be considered, cardiac function should be accurately measured and the cumulative dosage should be limited; otherwise, a new anthracycline alternative or liposome may be used to reduce anthracycline-induced cardiotoxicity.

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

References

1. Geisberg CA, Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. *Curr Hypertens Rep.* 2010;12:404–10.
2. Vasanthakumar A, Kattusamy K, Prasad R. Regulation of daunorubicin biosynthesis in *Streptomyces peucetius* - feed forward and feedback transcriptional control. *J Basic Microbiol.* 2013; 53:636–44.

3. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of adriamycin cardiotoxicity. *Cancer*. 1973;32(2):302-14.
4. Von Hoff DD, Layard MW, Basa P, Davis HL Jr, Von Hoff AL, Rozenzweig M, et al. Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med*. 1979;91(5):710-17.
5. Hershman DL, Shao T. Anthracycline cardiotoxicity after breast cancer treatment. *Oncology (Williston Park)*. 2009;23(3):227-34.
6. López-González A, Diz P, Gutierrez L, Almagro E, García Palomo A, Provencio M. The role of anthracyclines in small cell lung cancer. *Ann Transl Med*. 2013;1(1):5.
7. Shinohara N, Nonomura K, Tanaka M, Nagamori S, Takakura F, Seki T et al. Prophylactic chemotherapy with anthracyclines (Adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. *Cancer Chemother Pharmacol*. 1994;35(1):S41.
8. Ilson DH. Esophageal cancer chemotherapy: recent advances. *Gastrointest Cancer Res*. 2008;2(2):85–92.
9. Ashraf N, Kim R. Treatment of Gastric and Gastroesophageal Cancers—Do We Really Need Anthracyclines? *JAMA Oncol*. 2017;3(9):1172–3.
10. Brown KS. Chemotherapy and other systemic therapies for hepatocellular carcinoma and liver metastases. *Semin Intervent Radiol*. 2006;23(1):99–108.
11. Matuszczyk A, Petersenn S, Bockisch A, Gorges R, Sheu SY, Veit P et al. Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium. *Horm Metab Res*. 2008;40(3):210-13.
12. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, van't Veer MB, Baaijens MH, Boer JP et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. *Blood*. 2007;109(5):1878-86.
13. Luminari S, Montanini A, Federico M. Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphoma. *Hematol Rep*. 2011;3(3s):e4.
14. Pulini S, Rupoli S, Goteri G, Pimpinelli N, Alterini R, Tasseti A et al. Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas. *Haematologica*. 2007;92(5):686-9.
15. Bassan R, Lerede T, Rambaldi A, Buelli M, Viero P, Barbui T. The use of anthracyclines in adult acute lymphoblastic leukemia. *Haematologica*. 1995;80(3):280-91.
16. Pasvolsky O, Morelli O, Rozovski U, Vaturi M, Wolach O, Amitai I et al. Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation. *Clin Lymphoma Myeloma Leuk*. 2019;19(7):e343-e348.
17. Wagner MJ, Livingston JA, Patel SR, Benjamin RS. Chemotherapy for Bone Sarcoma in Adults. *J Oncol Pract*. 2016;12:208-16
18. In GK, Hu JS, Tseng WW. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. *Ther Adv Med Oncol*. 2017;9(8):533–50.
19. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. *Prog Cardiovasc Dis*. 2007;49:330-52.
20. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics Adriamycin and daunorubicin. *Biochem Pharmacol*. 1999;57:727-41.
21. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. *Pharmacol Rev*. 2004;56:185-229.
22. Cirillo R, Sacco G, Venturella S, Brightwell J, Giachetti A, Manzini S. Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat. *J Cardiovasc Pharmacol*. 2000;35:100-8.
23. de Graaf H, Dolsma WV, Willemse PH, van der Graaf WT, Sleijfer DT, de Vries EG et al. Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer. *Br J Cancer*. 1997;76:943-5.
24. Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. *Am Heart J*. 1998;136:362-3.
25. Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin-T in pediatric patients at risk for myocardial injury. *Circulation*. 1997;96:2641-8
26. Jaworski C, Mariani JA, Wheeler G, Kaye DM. Cardiac complications of thoracic irradiation. *J Am Coll Cardiol*. 2013;61:2319-28.
27. Jain D, Russell RR, Schwartz RG, Panjath GS, Aronow W. Cardiac complications of cancer therapy: Pathophysiology, identification, prevention, treatment, and future directions. *Curr Cardiol Rep*. 2017; 19:36.

28. Davies SM, Pearson AD, Craft AW. Toxicity of high-dose ifosfamide in children. *Cancer Chemother Pharmacol.* 1989;24:S8-10
29. Skinner R, Pearson AD, Price L, Coulthard MG, Craft AW. Nephrotoxicity after ifosfamide. *Arch Dis Child.* 1990;65:732-8
30. Dvorak SN, Kurniali PC. BCNU (Bis-chloroethylnitrosourea, Carmustine) Toxicity Presented as a Large Pleural Effusion 60 Days Post Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma. *Cureus.* 2019;11(2):e4052
31. Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. *J Clin Oncol.* 1990;8(4):648-56.
32. Salmon SE. Nitrosoureas in multiple myeloma. *Cancer Treat Rep.* 1976;60:789-94
33. Neppalli AK, Shizuru J, Johnston LJ, Muffly LS, Weng WK, Negrin R et al. Long-term outcomes of high-dose melphalan and carmustine followed by autologous hematopoietic cell transplantation for multiple myeloma. *J Clin Oncol.* 2016;34(15):8026-36
34. Kanj SS, Sharara AL, Shpall EJ, Jones RB, Peters WP. Myocardial ischemia associated with high dose carmustine infusion. *Cancer.* 1991;68:1910-2
35. Genet P, Pulik M, Gallet B, Lionnet F, Jondeau K, Touahri T et al. Acute myocardial ischemia after high-dose therapy with BEAM regimen. *Bone Marrow Transplant.* 2002;30:253-4.
36. Takvorian T, Parker LM, Hochberg FH, Canellos GP. Autologous bone marrow transplantation: host effects of high-dose BCNU. *J Clin Oncol.* 1983;1:610-20.
37. Henner W, Peters WP, Eder JP, Antman K, Schnipper L. Pharmacokinetics and immediate effects of high-dose carmustine in man. *Cancer Treat Rep.* 1986;70:877-80.
38. Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X. Molecular mechanisms of cisplatin resistance in cervical cancer. *Drug Des Devel Ther.* 2016;10:1885-95.
39. Aldossary SA. Review on Pharmacology of Cisplatin: Clinical Use, Toxicity and Mechanism of Resistance of Cisplatin. *Biomed Pharmacol J.* 2019;12(1):7-15.
40. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. *Eur J Pharmacol.* 2014;740:364-78.
41. Jakubowski AA, Kemeny N. Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5-fluorouracil. *Cancer.* 1988;62:266-9.
42. Hu Y, Sun B, Zhao B, Mei D, Gu Q, Tian Z. Cisplatin-induced cardiotoxicity with midrange ejection fraction: A case report and review of the literature. *Medicine.* 2018;97:52(e13807)
43. Bano N, Najam R, Qazi F. Adverse cardiac manifestations of cisplatin- a review. *Int J Pharm Sci Rev Res.* 2013;18(1):80-5.
44. Yusuf SW, Razeghi P, Yeh ET. The diagnosis and management of cardiovascular disease in cancer patients. *Curr Probl Cardiol.* 2008;33(4):163-96.
45. Khan S, Chen CL, Brady MS, Parameswaran R, Moore R, Hassoun H et al. Unstable angina associated with cisplatin and carboplatin in a patient with advanced melanoma. *J Clin Oncol.* 2012;30(18):e163-e164.
46. Ryberg M. Recent advances in cardiotoxicity of anticancer therapies. *Am Soc Clin Oncol Educ Book.* 2012;32:555-9.
47. Moore RA, Adel N, Riedel E, Bhutani M, Feldman DR, Tabbara NE et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. *J Clin Oncol.* 2011;29(25):3466-73.
48. Amit L, Ben-Aharon I, Tichler T, Inbar E, Sulkes A, Stemmer S. Cisplatin-induced posterior reversible encephalopathy syndrome-brief report and review of the literature. *J Behav Brain Sci.* 2012;2(1):97-101.